Immunoglobulin therapy in the 21st century: the dark side of the moon
In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (124 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993541099504498 |
---|---|
ctrlnum |
(CKB)3710000000824742 (oapen)https://directory.doabooks.org/handle/20.500.12854/49987 (EXLCZ)993710000000824742 |
collection |
bib_alma |
record_format |
marc |
spelling |
Albert Farrugia auth Immunoglobulin therapy in the 21st century: the dark side of the moon Immunoglobulin therapy in the 21st century Frontiers Media SA 2015 1 electronic resource (124 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage. English Immunedeficienc Manufacture adverse events Personalised treatment Immunoglobulin Therapy Mechanism 2-88919-703-4 Isabella Quinti auth Marcella Visentini auth |
language |
English |
format |
eBook |
author |
Albert Farrugia |
spellingShingle |
Albert Farrugia Immunoglobulin therapy in the 21st century: the dark side of the moon Frontiers Research Topics |
author_facet |
Albert Farrugia Isabella Quinti Marcella Visentini |
author_variant |
a f af |
author2 |
Isabella Quinti Marcella Visentini |
author2_variant |
i q iq m v mv |
author_sort |
Albert Farrugia |
title |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_full |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_fullStr |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_full_unstemmed |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_auth |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_alt |
Immunoglobulin therapy in the 21st century |
title_new |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
title_sort |
immunoglobulin therapy in the 21st century: the dark side of the moon |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2015 |
physical |
1 electronic resource (124 p.) |
isbn |
2-88919-703-4 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT albertfarrugia immunoglobulintherapyinthe21stcenturythedarksideofthemoon AT isabellaquinti immunoglobulintherapyinthe21stcenturythedarksideofthemoon AT marcellavisentini immunoglobulintherapyinthe21stcenturythedarksideofthemoon AT albertfarrugia immunoglobulintherapyinthe21stcentury AT isabellaquinti immunoglobulintherapyinthe21stcentury AT marcellavisentini immunoglobulintherapyinthe21stcentury |
status_str |
n |
ids_txt_mv |
(CKB)3710000000824742 (oapen)https://directory.doabooks.org/handle/20.500.12854/49987 (EXLCZ)993710000000824742 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Immunoglobulin therapy in the 21st century: the dark side of the moon |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1787548883999522816 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04619nam-a2200373z--4500</leader><controlfield tag="001">993541099504498</controlfield><controlfield tag="005">20231214132823.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2015 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000824742</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49987</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000824742</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Albert Farrugia</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunoglobulin therapy in the 21st century: the dark side of the moon</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Immunoglobulin therapy in the 21st century</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (124 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunedeficienc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Manufacture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse events</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Personalised treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunoglobulin Therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mechanism</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-703-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Isabella Quinti</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marcella Visentini</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:06 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-08-13 16:41:26 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337072450004498&Force_direct=true</subfield><subfield code="Z">5337072450004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337072450004498</subfield></datafield></record></collection> |